Brought to you by 
Sepracor and ArQule in drug discovery deal for HIV and hep. B
13 Jul 1999
Executive Summary
Sepracor will screen ArQule's Mapping Array libraries of small organic, pure compounds against its collection of mutant HIV proteases, in a drug discovery collaboration for therapeutics that target resistant HIV strains and hepatitis B.
Deal Industry
-
Pharmaceuticals
- Chiral Chemistry
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sepracor and ArQule in drug discovery deal for HIV and hep. B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice